LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease

被引:2
|
作者
Keeney, Matthew T. [1 ,2 ,3 ]
Rocha, Emily M. [1 ,2 ]
Hoffman, Eric K. [1 ,2 ]
Farmer, Kyle [1 ,2 ]
Di Maio, Roberto [1 ,2 ]
Weir, Julie [1 ,2 ]
Wagner, Weston G. [1 ,2 ]
Hu, Xiaoping [1 ,2 ]
Clark, Courtney L. [1 ,2 ]
Castro, Sandra L. [1 ,2 ]
Scheirer, Abigail [1 ,2 ]
Fazzari, Marco [3 ]
De Miranda, Briana R. [1 ,4 ]
Pintchovski, Sean A. [5 ]
Shrader, William D. [5 ]
Pagano, Patrick J. [3 ,6 ]
Hastings, Teresa G. [1 ,2 ]
Greenamyre, J. Timothy [1 ,2 ]
机构
[1] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA
[4] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL USA
[5] Acurex Biosci, San Carlos, CA USA
[6] Univ Pittsburgh, Sch Med, Vasc Med Inst, Pittsburgh, PA USA
关键词
OXIDATIVE STRESS; KINASE-ACTIVITY; COMPLEX-I; PHOSPHORYLATION; INHIBITOR; MUTATIONS; P47PHOX; GENE;
D O I
10.1126/scitranslmed.adl3438
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oxidative stress has long been implicated in Parkinson's disease (PD) pathogenesis, although the sources and regulation of reactive oxygen species (ROS) production are poorly defined. Pathogenic mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are associated with increased kinase activity and a greater risk of PD. The substrates and downstream consequences of elevated LRRK2 kinase activity are still being elucidated, but overexpression of mutant LRRK2 has been associated with oxidative stress, and antioxidants reportedly mitigate LRRK2 toxicity. Here, using CRISPR-Cas9 gene-edited HEK293 cells, RAW264.7 macrophages, rat primary ventral midbrain cultures, and PD patient-derived lymphoblastoid cells, we found that elevated LRRK2 kinase activity was associated with increased ROS production and lipid peroxidation and that this was blocked by inhibitors of either LRRK2 kinase or NADPH oxidase 2 (NOX2). Oxidative stress induced by the pesticide rotenone was ameliorated by LRRK2 kinase inhibition and was absent in cells devoid of LRRK2. In a rat model of PD induced by rotenone, a LRRK2 kinase inhibitor prevented the lipid peroxidation and NOX2 activation normally seen in nigral dopaminergic neurons in this model. Mechanistically, LRRK2 kinase activity was shown to regulate phosphorylation of serine-345 in the p47(phox) subunit of NOX2. This, in turn, led to translocation of p47(phox) from the cytosol to the membrane-associated gp91(phox) (NOX2) subunit, activation of the NOX2 enzyme complex, and production of ROS. Thus, LRRK2 kinase activity may drive cellular ROS production in PD through the regulation of NOX2 activity.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Analysis of LRRK2 variants in Parkinson's disease
    Au, W. L.
    Ho, P.
    Zhao, Y.
    Tan, L. C. S.
    Tan, E. K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S468 - S468
  • [22] LRRK2 is reduced in Parkinson’s disease gut
    Adrien de Guilhem de Lataillade
    Jérémy Verchere
    Thibauld Oullier
    Alice Prigent
    Tony Durand
    Carolina Pellegrini
    Michel Neunlist
    Thierry Baron
    Malvyne Rolli-Derkinderen
    Pascal Derkinderen
    Acta Neuropathologica, 2021, 142 : 601 - 603
  • [23] Mutations in LRRK2 as a cause of Parkinson's disease
    Giasson, Benoit I.
    Van Deerlin, Vivianna M.
    NEUROSIGNALS, 2008, 16 (01) : 99 - 105
  • [24] LRRK2, lysosome damage, and Parkinson's disease
    Bentley-DeSousa, Amanda
    Clegg, Devin
    Ferguson, Shawn M.
    CURRENT OPINION IN CELL BIOLOGY, 2025, 93
  • [25] LRRK2 is reduced in Parkinson's disease gut
    de Guilhem de Lataillade, Adrien
    Verchere, Jeremy
    Oullier, Thibauld
    Prigent, Alice
    Durand, Tony
    Pellegrini, Carolina
    Neunlist, Michel
    Baron, Thierry
    Rolli-Derkinderen, Malvyne
    Derkinderen, Pascal
    ACTA NEUROPATHOLOGICA, 2021, 142 (03) : 601 - 603
  • [26] Lrrk2 pathogenic substitutions in Parkinson's disease
    Mata, IF
    Kachergus, JM
    Taylor, JP
    Lincoln, S
    Aasly, J
    Lynch, T
    Hulihan, MM
    Cobb, SA
    Wu, RM
    Lu, CS
    Lahoz, C
    Wszolek, ZK
    Farrer, MJ
    NEUROGENETICS, 2005, 6 (04) : 171 - 177
  • [27] Lrrk2 pathogenic substitutions in Parkinson's disease
    Ignacio F. Mata
    Jennifer M. Kachergus
    Julie P. Taylor
    Sarah Lincoln
    Jan Aasly
    Timothy Lynch
    Mary M. Hulihan
    Stephanie A. Cobb
    Ruey-Meei Wu
    Chin-Song Lu
    Carlos Lahoz
    Zbigniew K. Wszolek
    Matthew J. Farrer
    Neurogenetics, 2005, 6 : 171 - 177
  • [28] LRRK2 as a therapeutic target in Parkinson's disease
    Tan, E. K.
    Schapira, A. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (04) : 545 - 546
  • [29] LRRK2 and the Endolysosomal System in Parkinson's Disease
    Erb, Madalynn L.
    Moore, Darren J.
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (04) : 1271 - 1291
  • [30] Targeting LRRK2 mutations in Parkinson's disease
    Lesniak, Robert K.
    Nichols, Robert Jeremy
    Smith, Mark
    Montine, Thomas J.
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (16) : 1167 - 1170